Geoffroy V.
- Country
- France
- Department
- Onco-hématologie
Research Overview
- Evaluation of Venetoclax and Azacitidine Combination Therapy Versus Placebo and Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome
- Phase I/II Evaluation of Sulfasalazine, Idarubicin, and Cytarabine in Newly Diagnosed Non-Favorable Acute Myeloid Leukemia Patients Aged 60 and Above
- Phase III Randomized Open-Label Multicenter Trial of Ruxolitinib vs. Hydroxycarbamide or Peginterferon Alfa-2a in High-Risk Polycythemia Vera Patients
Data & Insights
Has run more than one trial at 20 of 110 partner sites.
Specializations
Myeloproliferative Disorders
Specialized in treating various forms of myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Experienced in managing polycythemia vera, particularly focusing on high-risk cases.
- Spleen Volume Management
- Symptom Score Reduction
- Thrombosis Prevention
Active in evaluating novel therapeutic approaches for myeloproliferative conditions.
Acute Myeloid Leukemia
Focuses on developing treatment strategies for non-favorable acute myeloid leukemia, particularly in elderly patients. Investigates innovative combination therapies incorporating conventional chemotherapy with novel agents.
- Elderly Patient Care
- Novel Drug Combinations
- Complete Remission Assessment
Specializes in evaluating treatment responses through minimal residual disease monitoring.
Myelodysplastic Syndrome
Concentrated on treating higher-risk myelodysplastic syndrome with innovative therapeutic combinations. Expertise in evaluating survival outcomes in newly diagnosed patients.
- Treatment-Naïve Patients
- Combination Therapy Approaches
- Overall Survival Assessment
Focuses on developing standard-of-care treatments for advanced myelodysplastic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.